Prevalence of Cardiovascular Disease in Patients with Prostate Cancer: STOP-6

The following presentation was made at the 6th Symposium on the Treatment of Prostate Cancer (STOP-6), which was held in Lisbon, Portugal between the 14th and 16th October.

Dr. Alexander Lyon discusses the high cardiovascular events in prostate cancer patients and the GnRH agonists associated with elevated risk of CV events and GnRH antagonists has less toxicity in retrospective analysis.  Dr. Lyon also stresses the need to increase awareness of CV risk in the prostate cancer patients and guide

Biography:
Alexander Lyon
BHF Senior Lecturer and Consultant Cardiologists
Royal Brompton Hospital, London, UK
President of British Cardio-Oncology Society
Chair of HFA Cardio-Oncology Study Group of ESC